ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

ENDRA Life Sciences (NASDAQ: NDRA) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq Listing Qualifications Department on November 21, 2024, verifying its compliance with Listing Rule 5550(a)(2). This development allows ENDRA to maintain its Nasdaq listing and focus on implementing its new transformational business strategies, as previously discussed during their August conference call.

Positive

• Regained Nasdaq listing compliance, avoiding potential delisting risk
• Company can now focus on executing new business strategies without listing concerns

Negative

• Previous non-compliance with Nasdaq listing requirements indicates recent stock price weakness

Insights

Financial Analyst

Regaining Nasdaq compliance removes an immediate delisting threat for ENDRA Life Sciences, but investors should remain cautious. With a micro-cap market value of just $2.5M, the company remains vulnerable to future listing challenges. While maintaining Nasdaq listing provides better visibility and liquidity compared to OTC markets, the focus should be on the company's ability to execute its business transformation strategy and improve its financial position. The stock's recent price recovery above $1 will need to be sustained through fundamental business improvements rather than just technical compliance.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS^®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).

On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq’s maintenance requirements for listing.

“Now that we have regained compliance with Nasdaq’s listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22^nd conference call,” said Alex Tokman, acting Chief Executive Officer of ENDRA.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) and metabolic dysfunction-associated steatohepatitis (MASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241122279101/en/

Company Contact:

Richard Jacroux

Chief Financial Officer

investors@endrainc.com

www.endrainc.com



Investor Relations Contact:

Yvonne Briggs

Alliance Advisors IR

(310) 691-7100

ybriggs@allianceadvisors.com

Source: ENDRA Life Sciences Inc.

FAQ

When did ENDRA Life Sciences (NDRA) regain Nasdaq compliance?

ENDRA Life Sciences regained compliance with Nasdaq's minimum bid price requirement on November 21, 2024, as confirmed by the Nasdaq Listing Qualifications Department.

What Nasdaq requirement did ENDRA Life Sciences (NDRA) meet?

ENDRA Life Sciences met Nasdaq's Listing Rule 5550(a)(2), which pertains to the minimum bid price requirement for continued listing on the exchange.

What is ENDRA Life Sciences (NDRA) planning to focus on after regaining Nasdaq compliance?

ENDRA Life Sciences plans to focus on implementing its new transformational business strategies, which were previously discussed during their August 22nd conference call.